Bipartisan lawmakers urge Biden administration to increase scrutiny of U.S. clinical trials in China
In a recent letter, Republican John Moolenaar and Democrat Raja Krishnamoorthi highlighted concerns about intellectual property theft and forced participation of Uyghurs in clinical trials conducted in China. This collaboration between U.S. drug companies and Chinese military-run hospitals has raised ethical and security concerns. The FDA has been called upon to address these issues by October 1st.
Analysis:
Lawmakers are increasingly worried about China's involvement in the biotechnology industry, calling for stricter regulations and potential restrictions on business with certain Chinese biotech firms. This development could impact the future of U.S.-China healthcare collaborations and raise questions about the protection of intellectual property in clinical trials. Investors and stakeholders in the biotech sector should closely monitor these developments for potential implications on their investments and business operations.